If you do not find what you are looking for try searching with a different term or contact us.
This recorded webinar from the PS ROTA-R provides an overview of the fentanyl crisis impacting non-metropolitan rural communities, and the emerging issue of xylazine.
This recorded webinar from the National Council for Mental Wellbeing discusses emerging practices in Xylazine wound care.
WASHINGTON – The U.S. Drug Enforcement Administration is warning the American public of a sharp increase in the trafficking of fentanyl mixed with xylazine. Xylazine, also known as “Tranq,” is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use.
This infographic from the National Harm Reduction Coalition contains information on Xylazine in the drug supply.
This comprehensive guide provides information and recommendations regarding general health, safer use practices, common viral, fungal, parasitic, and other injection-related infections, overdose and overamp, tapering, withdrawal, medications for opioid use disorder, and seeking medical care.
In this recorded webinar, panelists provide a brief overview of Xylazine, a substance newly found in illicit drug supplies, and its impacts on the unsheltered community. Panelists will share their lived expertise with xylazine, its effects, organizational best practices for wound care, overdose response, and harm reduction.
This fact sheet is intended to guide healthcare professionals on the clinical management of Xylazine use and harm reduction strategies for their patients.
The Southern Nevada Health District (SNHD) is urging heightened public awareness of the health dangers associated with xylazine, an animal tranquilizer that is increasingly being found in the country’s illicit drug supply and linked to overdose deaths throughout the United States. Xylazine, also known as “tranq,” is not approved for human consumption. It can be life-threatening and is especially dangerous when combined with opioids such as fentanyl.
This document provides information on xylazine, a non-opioid veterinary tranquilizer used as an additive in illicit drug supplies, notably in combination with heroin and fentanyl. It discusses the effects of xylazine use, including sedation and potential risks such as hypotension and bradycardia. The document also emphasizes harm reduction interventions for individuals who may encounter xylazine in the drug supply, including the use of naloxone for responding to overdoses and the importance of wound identification and treatment.
This “Dear Colleague” letter from the Substance Abuse and Mental Health Services Administration (SAMHSA) provides a report on the risks of Xylazine.
The Good Samaritan Drug Overdose Act of 2015 (Senate Bill 459, Chapter 26, Statutes of Nevada 2015 NRS 453C.120) created various provisions addressing the opiate overdose epidemic that continues to claim over 300 lives per year in Nevada. The law prevents punitive actions against health professionals and any person who administers naloxone or calls 911 to assist someone who may be overdosing on opiates. It also provides immunity to persons seeking medical treatment for an opioid overdose for themselves or someone else. Learn more about the Good Samaritan Law.
Toll-free national overdose prevention, detection, life-saving crisis response and medical intervention services for people who use drugs while alone. Never Use Alone’s peer operators are available 24-hours a day, 7 days a week, 365 days a year.
Information about Xylazine, commonly referred to as tranq or tranq dope, an animal tranquilizer that is increasingly found in the illicit drug supply.
This pocket card from NYC.gov is a guide to wound care self-management for people who use drugs.